

Table S1. Changes of metabolic parameters at week 0 and week 12 after interleukin-17A blockade (secukinumab/ Cosentyx®) and stratified analysis by PASI-90 response at week 12

	All (n=99)		PASI-90+ at week12 (n=46)		PASI-90- at week12 (n=53)	
	W0	W12	W0	W12	W0	W12
HsCRP ⁺	3.7	2.2**	3.4	1.8*	4.0	2.8*
ESR ⁺	9	7	8	7	9	8
Sugar	98	103*	96	97	101	109*
UA	6.6	6.3*	6.5	6.3	6.7	6.3*
HDL	44	44	44	45	44	43
LDL	114	115	115	111	112	117
CHOL	185	188	184	186	185	191
TG	134	152*	129	141	139	161*
n-HDL	141	145	141	141	141	148
AIP	0.45	0.50*	0.42	0.45	0.47	0.54*

Mean, +Median. BW, Body weight; BMI, body mass index; Chol, cholesterol; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; n-HDL, non high-density lipoprotein; PASI, Psoriasis Area and Severity Index; TG, triglyceride. AIP, Atherogenic index of plasma (AIP = Log(TG/HDL_C). The paired t-test was used to analyze metabolic parameters between week 0 and week 12. Wilcoxon signed rank test was used to analyze the ESR and hs-CRP (1) between week 0 and week 12. *: p value was less than 0.05; **: p value was less than 0.001.